Olugbenga Olowokure , MD

Bachelor's Degree: University of Maiduguri 1997 (Medicine and Surgery)

Residency: St. John's Episcopal Hospital 2005 (Internal Medicine )

Fellowship: Mount Sinai School of Medicine 2009 (Hematology Oncology)

Medical Degree: University of Maiduguri 2007

American Board of Internal Medicine (Medical Oncology) (Certification Date: 11-12-2009 ) - (Recertification Date: to 12-25-2019 )

Esophageal Cancer

Hematology and Oncology

Medical Oncology

Ampullary Cancer

Anal Cancer

Appendix Cancer

Biliary Cancer

Cholangiocarcinoma

Colon Cancer

Intestinal Cancer

Liver Cancer

Neuroendocrine Cancer

Pancreatic Cancer

Peritoneal Cancer

Rectal Cancer

Small Bowel Cancer

Stomach Cancer

Hematology

Internal Medicine

Medical Oncology

Gastrointestinal oncology, Sickle Cell Disease, Hematology Oncology

07-2009 -To Present Assistant Professor of Medicine Gastrointestinal Oncology and Sickle Cell Disease, University of Cincinnati Hematology-Oncology, Cincinnati, Ohio

07-2010 -To Present Director of Inpatient Services (8CCP), University Hospital, Cincinnati, Ohio

07-2005 -06-2006 Sickle Cell Fellow, SUNY Down State & Kings County Hospital Center, Brooklyn, NYC

02-2002 -07-2002 Medical House Officer, GI Service, William Harvey Hospital, Ashford Kent U.K.

09-2001 -02-2002 Surgical House Officer, GI Oncology Service, William Harvey Hospital, Ashford Kent U.K.

03-1999 -02-2000 NYSC Doctor, Ibeju Lekki Health Center Lagos, Nigeria

12-1997 -03-1998 Volunteer - Administration, University of Maiduguri, Borno, Nigeria

Investigators:Olowokure, Olugbenga; Sohal, Davendra 09-01-2021 -08-31-2027 Pancreatic Cancer Network University of Cincinnati Cancer Center Role:Collaborator 0.00 Hold Level:Non Profit

Grant: #Mayo; UNI 305129 ACCRU membership Investigators:Olowokure, Olugbenga -11-30-2027 Mayo Clinic ACADEMIC AND COMMUNITY CANCER RESEARCH UNITED RESEARCH COORDINATING CENTER AGREEMENT Role:PI 0.00 Hold Level:Non Profit

Published Abstracts

OO Olowokure, Beg MS, S Ali, A Tandra, MM Safa, K Havlin, SA Ahmad (2010. ) Is Diabetes Mellitus Associated with Worse Outcomes in Pancreatic Cancer .[Abstract]ASCO,

OO Olowokure, PA Shi, JE Jang, S Serban, PS Frenette, GF Atweh, JL Gabrilove, C Miller (02-2010. ) Phase One Study of IVIg for Acute Pain Espisodes 4th Annual Sickle Cell Disease Research and Educational Symposium and Annual National Sickle Cell Scientific Meeting Hollywood Florida .[Abstract]

OO Olowokure, Jeske S, Tagawa St, Selzer J, Giannakakou P, Nanus DM (05-2010. ) Carboplatin plus Paclitaxel Therapy After Docetaxel in Men With Metastatic Castrate Resistant Prostate Cancer .[Abstract]

Peer Reviewed Publications

Jeske, Stephanie; Tagawa, Scott T; Olowokure, Olugbenga; Selzer, Jodi; Giannakakou, Paraskevi; Nanus, David M (2010. ) Carboplatin plus paclitaxel therapy after docetaxel in men with metastatic castrate resistant prostate cancer.Urologic oncology, , More Information

Olowokure, O; Fishman, M; Cromwell, C; Aledort, L (2009. ) DDAVP for von Willebrand menorrhagia--severe hyponatraemia, haemolysis, seizure, coma.!! Caution.Haemophilia : the official journal of the World Federation of Hemophilia, , 15 (3 ) ,837 More Information

Ge, Chunmin; Vilfranc, Chrystelle L; Che, Lixiao; Pandita, Raj K; Hambarde, Shashank; Andreassen, Paul R; Niu, Liang; Olowokure, Olugbenga; Shah, Shimul; Waltz, Susan E; Zou, Lee; Wang, Jiang; Pandita, Tej K; Du, Chunying (2019. ) The BRUCE-ATR Signaling Axis Is Required for Accurate DNA Replication and Suppression of Liver Cancer Development.Hepatology (Baltimore, Md.), , 69 (6 ) ,2608-2622 More Information

Kharofa, Jordan; Mierzwa, Michelle; Olowokure, Olugbenga; Sussman, Jeffrey; Latif, Tahir; Gupta, Anumeha; Xie, Changchun; Patel, Sameer; Esslinger, Hope; Mcgill, Brian; Wolf, Eric; Ahmad, Syed A (2019. ) Pattern of Marginal Local Failure in a Phase II Trial of Neoadjuvant Chemotherapy and Stereotactic Body Radiation Therapy for Resectable and Borderline Resectable Pancreas Cancer.American journal of clinical oncology, , 42 (3 ) ,247-252 More Information

Abou-Alfa, Ghassan K; Miksad, Rebecca A; Tejani, Mohamedtaki A; Williamson, Stephen; Gutierrez, Martin E; Olowokure, Olugbenga O; Sharma, Manish R; El Dika, Imane; Sherman, Matthew L; Pandya, Shuchi S (2019. ) A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.The oncologist, , 24 (2 ) ,161-e70 More Information

Sanoff, Hanna K; Goldberg, Richard M; Ivanova, Anastasia; O'Reilly, Seamus; Kasbari, Samer S; Kim, Richard D; McDermott, Ray; Moore, Dominic T; Zamboni, William; Grogan, William; Cohn, Allen Lee; Bekaii-Saab, Tanios S; Leonard, Gregory; Ryan, Theresa; Olowokure, Olugbenga O; Fernando, Nishan H; McCaffrey, John; El-Rayes, Bassel F; Horgan, Anne M; Sherrill, Gary Bradley; Yacoub, George Hosni; O'Neil, Bert H (2018. ) Multicenter, randomized, double-blind phase 2 trial of FOLFIRI with regorafenib or placebo as second-line therapy for metastatic colorectal cancer.Cancer, , 124 (15 ) ,3118-3126 More Information

Wakefield, Connor; Mehta, Parinda A; Corathers, Sarah; Geller, James; Gelfand, Michael; Olowokure, Olugbenga; Marsh, Rebecca A (2018. ) A First Report of Secondary Hemophagocytic Lymphohistiocytosis Associated With Papillary Thyroid Carcinoma.Journal of pediatric hematology/oncology, , 40 (2 ) ,e97-e98 More Information

Kim, Young; Stahl, Christopher C; Makramalla, Abouelmagd; Olowokure, Olugbenga O; Ristagno, Ross L; Dhar, Vikrom K; Schoech, Michael R; Chadalavada, Seetharam; Latif, Tahir; Kharofa, Jordan; Bari, Khurram; Shah, Shimul A (2017. ) Downstaging therapy followed by liver transplantation for hepatocellular carcinoma beyond Milan criteria.Surgery, , 162 (6 ) ,1250-1258 More Information

Wise-Draper, Trisha M; Moorthy, Ganesh; Salkeni, Mohamad A; Karim, Nagla Abdel; Thomas, Hala Elnakat; Mercer, Carol A; Beg, M Shalaan; O'Gara, Sue; Olowokure, Olugbenga; Fathallah, Hassana; Kozma, Sara C; Thomas, George; Rixe, Olivier; Desai, Pankaj; Morris, John C (2017. ) A Phase Ib Study of the Dual PI3K/mTOR Inhibitor Dactolisib (BEZ235) Combined with Everolimus in Patients with Advanced Solid Malignancies.Targeted oncology, , 12 (3 ) ,323-332 More Information

Xia, Brent T; Fu, Baojin; Wang, Jiang; Kim, Young; Ahmad, S Ameen; Dhar, Vikrom K; Levinsky, Nick C; Hanseman, Dennis J; Habib, David A; Wilson, Gregory C; Smith, Milton; Olowokure, Olugbenga O; Kharofa, Jordan; Al Humaidi, Ali H; Choe, Kyuran A; Abbott, Daniel E; Ahmad, Syed A (2017. ) Does radiologic response correlate to pathologic response in patients undergoing neoadjuvant therapy for borderline resectable pancreatic malignancy?.Journal of surgical oncology, , 115 (4 ) ,376-383 More Information

Agarwal, Rishi; Sendilnathan, Arun; Siddiqi, Nabeela Iffat; Gulati, Shuchi; Ghose, Abhimanyu; Xie, Changchun; Olowokure, Olugbenga Olanrele (2016. ) Advanced biliary tract cancer: clinical outcomes with ABC-02 regimen and analysis of prognostic factors in a tertiary care center in the United States.Journal of gastrointestinal oncology, , 7 (6 ) ,996-1003 More Information

O'Neil, B H; Scott, A J; Ma, W W; Cohen, S J; Leichman, L; Aisner, D L; Menter, A R; Tejani, M A; Cho, J K; Granfortuna, J; Coveler, L; Olowokure, O O; Baranda, J C; Cusnir, M; Phillip, P; Boles, J; Nazemzadeh, R; Rarick, M; Cohen, D J; Radford, J; Fehrenbacher, L; Bajaj, R; Bathini, V; Fanta, P; Berlin, J; McRee, A J; Maguire, R; Wilhelm, F; Maniar, M; Jimeno, A; Gomes, C L; Messersmith, W A (2015. ) A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , 26 (12 ) ,2505 More Information

Yellu, Mahender R; Olowokure, Olugbenga (2015. ) Simultaneous presentation of pancreatic cancer in a genetically unrelated couple.BMJ case reports, , 2015 , More Information

O'Neil, B H; Scott, A J; Ma, W W; Cohen, S J; Leichman, L; Aisner, D L; Menter, A R; Tejani, M A; Cho, J K; Granfortuna, J; Coveler, A L; Olowokure, O O; Baranda, J C; Cusnir, M; Phillip, P; Boles, J; Nazemzadeh, R; Rarick, M; Cohen, D J; Radford, J; Fehrenbacher, L; Bajaj, R; Bathini, V; Fanta, P; Berlin, J; McRee, A J; Maguire, R; Wilhelm, F; Maniar, M; Jimeno, A; Gomes, C L; Messersmith, W A (2015. ) A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine versus gemcitabine alone in patients with previously untreated metastatic pancreatic cancer.Annals of oncology : official journal of the European Society for Medical Oncology, , 26 (9 ) ,1923-9 More Information

Rixe, Olivier; Puzanov, Igor; LoRusso, Patricia M; Cohen, Roger B; Morris, John C; Olowokure, Olugbenga O; Yin, Jian Y; Doroumian, Séverine; Shen, Liji; Olszanski, Anthony J (2015. ) Phase I dose-escalation study of cabazitaxel administered in combination with gemcitabine in patients with metastatic or unresectable advanced solid malignancies.Anti-cancer drugs, , 26 (7 ) ,785-92 More Information

Deeb, Ayham; Haque, Sulsal-Ul; Olowokure, Olugbenga (2015. ) Pulmonary metastases in pancreatic cancer, is there a survival influence?.Journal of gastrointestinal oncology, , 6 (3 ) ,E48-51 More Information

Yellu, Mahender; Deeb, Ayham; Olowokure, Olugbenga (2015. ) Overview of Recent Trends in the Management of Metastatic Anal Cancer.World journal of oncology, , 6 (1 ) ,311-315 More Information

Shi, Patricia Ann; Manwani, Deepa; Olowokure, Olugbenga; Nandi, Vijay (2014. ) Serial assessment of laser Doppler flow during acute pain crises in sickle cell disease.Blood cells, molecules & diseases, , 53 (4 ) ,277-82 More Information

Haque, Sulsal; Choe, Kyuran; Olowokure, Olugbenga (2014. ) Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib.Journal of gastrointestinal oncology, , 5 (6 ) ,E109-12 More Information

Beg, Muhammad Shaalan; Dwivedi, Alok Kumar; Ahmad, Syed Arif; Ali, Sadia; Olowokure, Olugbenga (2014. ) Impact of diabetes mellitus on the outcome of pancreatic cancer.PloS one, , 9 (5 ) ,e98511 More Information

Olowokure, Olugbenga; Qi, Xiaoyang (2014. ) Pancreatic cancer: current standards, working towards a new therapeutic approach.Expert review of anticancer therapy, , 14 (5 ) ,495-7 More Information

Singeltary, Brian; Ghose, Abhimanyu; Sussman, Jeffrey; Choe, Kyuran; Olowokure, Olugbenga (2014. ) Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal stromal tumor.Journal of gastrointestinal oncology, , 5 (1 ) ,E27-9 More Information

Olowokure, Olugbenga; Torregroza-Sanchez, Maria Patricia; Bedoya-Apraez, Ivan Dario (2013. ) Gemcitabine plus Nab-Paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC).Journal of gastrointestinal oncology, , 4 (2 ) ,E16-8 More Information

Grewal, Sanjeet S; McClaine, Rebecca J; Schmulewitz, Nathan; Alzahrani, Mohammed A; Hanseman, Dennis J; Sussman, Jeffery J; Smith, Milton; Choe, Kyuran A; Olowokure, Olugbenga; Mierzwa, Michelle; Ahmad, Syed A (2011. ) Factors associated with recidivism following pancreaticoduodenectomy.HPB : the official journal of the International Hepato Pancreato Biliary Association, , 13 (12 ) ,869-75 More Information

Yellu M.;Kamireddy C.;Olowokure O. (09-27-2017. ) Pancreatic cancer epidemiology and environmental risk factors.Current and Emerging Therapies in Pancreatic Cancer, , 1-22 More Information

Bekaii-Saab T.; Cohn A.; El-Rayes B.; Fernando N.; Goldberg R.M.; Grogan W.; Horgan A.; Ivanova A.; Kasbari S.; Kim R.; McCaffrey J.; McDermott R.; Moore D.; Olowokure O.; O'Neil B.; O'Reilly S.; Ryan T.; Sanoff H.; Sherrill G.; Yacoub G. (10-01-2016. ) A multi-center, randomized, double-blind phase II trial of FOLFIRI + regorafenib or placebo for pati.Annals of Oncology, , 27 ,vi153 More Information

O'Neil B.H.;Scott A.J.;Ma W.W.;Cohen S.J.;Aisner D.L.;Menter A.R.;Tejani M.A.;Cho J.K.;Granfortuna J.;Coveler A.L.;Olowokure O.O.;Baranda J.C.;Cusnir M.;Phillip P.;Boles J.;Nazemzadeh R.;Rarick M.;Cohen D.J.;Radford J.;Fehrenbacher L.;Bajaj R.;Bathini V.;Fanta P.;Berlin J.;McRee A.J.;Maguire R.;Wilhelm F.;Maniar M.;Jimeno A.;Gomes C.L.;Messersmith W.A. (06-18-2016. ) Erratum: A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemci.Annals of Oncology, , 27 (6 ) ,1180 More Information

Agarwal R.;Sendilnathan A.;Siddiqi N.;Gulati S.;Ghose A.;Xie C.;Olowokure O. (01-01-2016. ) Advanced biliary tract cancer: Clinical outcomes with ABC-02 regimen and analysis of prognostic fact.Journal of Gastrointestinal Oncology, , 7 (6 ) ,996-1003 More Information

O'Neil B.H.;Scott A.J.;Ma W.W.;Cohen S.J.;Leichman L.;Aisner D.L.;Menter A.R.;Tejani M.A.;Cho J.K.;Granfortuna J.;Coveler L.;Olowokure O.O.;Baranda J.C.;Cusnir M.;Phillip P.;Boles J.;Nazemzadeh R.;Rarick M.;Cohen D.J.;Radford J.;Fehrenbacher L.;Bajaj R.;Bathini V.;Fanta P.;Berlin J.;McRee A.J.;Maguire R.;Wilhelm F.;Maniar M.;Jimeno A.;Gomes C.L.;Messersmith W.A. (12-01-2015. ) A phase II/III randomized study to compare the efficacy and safety of rigosertib plus gemcitabine ve.Annals of Oncology, , 26 (12 ) ,2505 More Information

Deeb A.;Haque S.;Olowokure O. (01-01-2015. ) Pulmonary metastases in pancreatic cancer, is there a survival influence?.Journal of Gastrointestinal Oncology, , 6 (3 ) ,E48-E51 More Information

Yellu M.;Deeb A.;Olowokure O. (01-01-2015. ) Overview of recent trends in the management of metastatic anal cancer.CJAM Canadian Journal of Addiction Medicine, , 6 (1 ) ,311-315 More Information

Manwani D.;Chen G.;Carullo V.;Serban S.;Olowokure O.;Jang J.;Huggins M.;Cohen H.W.;Billett H.;Atweh G.F.;Frenette P.S.;Shi P.A. (01-01-2015. ) Single-dose intravenous gammaglobulin can stabilize neutrophil Mac-1 activation in sickle cell pain .American Journal of Hematology, , 90 (5 ) ,381-385 More Information

Haque S.;Choe K.;Olowokure O. (01-01-2014. ) Bilateral above knee amputations after prolonged exposure to sorafenib and trebananib.Journal of Gastrointestinal Oncology, , 5 (6 ) ,E109-E112 More Information

Singeltary B.;Ghose A.;Sussman J.;Choe K.;Olowokure O. (01-01-2014. ) Durable response with a combination of imatinib and sorafenib in KIT exon 17 mutant gastrointestinal.Journal of Gastrointestinal Oncology, , 5 (1 ) , More Information

Olowokure O.;Torregroza-Sanchez M.;Bedoya-Apraez I. (01-01-2013. ) Gemcitabine plus nab-paclitaxel with chemoradiation in locally advanced pancreatic cancer (LAPC).Journal of Gastrointestinal Oncology, , 4 (2 ) , More Information

Braverman A.S.;Nehra A.;Olowokure O.;Raftery T.;Gillette P.;Weedon J.;Olivier T.;Belyayeva I.;Deitch J. (06-01-2008. ) Perforator and axial venous insufficiency in sickle cell disease patients with and without leg ulcer .Journal for Vascular Ultrasound, , 32 (2 ) ,79-81

N'Guessan, Kombo F; Davis, Harold W; Chu, Zhengtao; Vallabhapurapu, Subrahmanya D; Lewis, Clayton S; Franco, Robert S; Olowokure, Olugbenga; Ahmad, Syed A; Yeh, Jen Jen; Bogdanov, Vladimir Y; Qi, Xiaoyang (2020. ) Enhanced Efficacy of Combination of Gemcitabine and Phosphatidylserine-Targeted Nanovesicles against Pancreatic Cancer.Molecular therapy : the journal of the American Society of Gene Therapy, , 28 (8 ) ,1876-1886 More Information

Barrord, Michelle; Ahmad, Syed; Patel, Sameer; Olowokure, Olugbenga; Sussman, Jeffrey; Smith, Milton; Poreddy, Sampath; Esslinger, Hope; Latif, Tahir; Choe, Kyuran; Kharofa, Jordan (2020. ) Patterns of Failure After Neoadjuvant Stereotactic Body Radiation Therapy or Fractionated Chemoradiation in Resectable and Borderline Resectable Pancreatic Cancer.Pancreas, , 49 (7 ) ,941-946 More Information

Invited Presentations

Olugbenga Olowokure, MD (01-2010. ) Gastric and Esophageal Cancer 2010 Medical Update .University of Cincinnati, Ohio. Level:Department

Olugbenga Olowokure, MD (12-2009. ) Sorafenib in the Treatment of Patients with Unresectable Hepatocellular Carcinoma .University of Cincinnati, Ohio. Level:Department

Olugbenga Olowokure, MD (11-2009. ) Esophageal and Gastric Cancer: Medical Oncology 2009 Update .GI Oncology Cancer Symposium, University of Cincinnati, Ohio. Level:Local

Olugbenga Olowokure, MD (09-2009. ) Cancer and Cancer Prevention for the at Risk Population: Who Provides The Care? Screening, Prevention Guidelines and Current Chemotherapy Options in Colorectal Cancer .

Olugbenga Olowokure, MD (06-2009. ) High Dose IVIG for Acute Pain Espisodes in Sickle Cell Disease: Hematology Grand Rounds .Mount Sinai School of Medicine NYC.

Olugbenga Olowokure, MD (02-2009. ) DDAVP for VonWillebrand Memorrhagia; Hematology Grand Rounds .Mount Sinai School of Medicine NYC.

Olugbenga Olowokure, MD High Dose IVIG for Acute Pain Espisodes in Sickle Cell Disease .SUNY Downstate. Level:University

Hematology/Oncology, Cancer, Oncology, Sickle Cell, GI Oncology

To Present -To Present: American College of Physicians

To Present -To Present: American Medical Association

To Present -To Present: American Society of Hematology

To Present -To Present: American Society of Clinical Oncology

Academic - Vontz Center for Molecular Studies
3125 Eden Avenue
Cincinnati  Ohio, 45267
Phone: 513-558-2113
Fax: 513-558-2124
olugbenga.olowokure@uc.edu